LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
602 IndexCancer (Contd.)
nasopharyngeal
EBV and, 52, 106, 111
symptoms of, 197
treatment, adjuvant
chemotherapy for, 201
types of, 197
of ovaries
BAX overexpression in, 307, 312
BRCA mutation and, 137,
139–140
BRCA1 mutation and, 305, 311
BSO in, 152, 158
CA-125 in, 306, 311, 314
clinical surveillance of, 310, 314
CT in, 168, 181
endometrial cancer and, 309,
313, 314
germ cell tumors and, 309, 313
granulosa cell tumors, 313
hormonal therapy for, 307, 312
immunostains on, 309, 314
Lynch syndrome and, 153, 159
MRI in, 168, 181
mucinous tumor and, 309, 314
multiparity and, 306, 312
oral contraceptives and, 308,
311, 312
ovary removal and, 311
platinum-based chemotherapy
for, 308, 309, 312, 314
PTEN mutations in, 307, 312
relapse of, 308, 312–313
risk factors for, 306, 312
sex cord–stromal tumors and,
313
surgical staging series, 311
TP53 mutation in, 307, 312
transvaginal ultrasound in, 311
ultrasound in, 168, 181
of pancreas
ABO blood group and, 246, 251
African American men and,
243, 247
BRCA2 and, 246, 251
CA 19-9 and, 243, 247
CHRNA3 gene and, 73, 76
cigarette smoking and, 243, 247
cirrhosis and, 243, 247
endoscopic ultrasound of, 249
FOLFIRINOX in, 245, 250–251
FOLFOX6 and, 246, 251
gemcitabine and erlotinib
combination therapy in,
245, 250
gemcitabine in, 87, 92
K-ras oncogene and, 243, 248
laparoscopy and multiphase CT
of, 244, 248–249PanIN and, 243, 247–248
p16-mediated CDK inhibition,
246, 251
risk factors for, 243, 246, 247,
251
telomere shortening, 246, 251
TGF-expression in, 246, 251
tobacco use and, 34, 44
TP53 gene mutation in, 251
PARP inhibitors in, 126, 131–132
of penis, 39, 51, 295
polyomaviruses in, 40, 53
of prostate
African-American men and,
144, 147
castrate-resistant, 287, 295
dietary or lifestyle component
in, 286, 294
docetaxel-based chemotherapy
for, 286, 294
Gleason score and, 284, 292
GSTloss and, 286, 294
interstitial radiotherapy and,
284, 292
MRI of, 169, 181–182
NKX3.1 and, 286, 294
and osteoblastic lesions, 23, 31
radical retropubic
prostatectomy and, 284,
292
risk factors for, 286, 294
screening, serum PSA in, 181
three-dimensional conformal
radiotherapy and, 284,
292
TMPRSS2 and, 281, 286, 290,
294
vitamin E and, 283, 291
radiation-induced, 60, 66
recall bias and, 61, 66
of rectum
neoadjuvant chemoradiotherapy
in, 271, 276
transanal excision for, 271, 276
renal cell
and clear cell histology, 108,
112
MET mutation and, 279, 288
orthopedic resection, 280, 288
poor-risk features in, 280, 289
treatment, interferon-in, 280,
289
types of, 288
risk factors of, 57, 63
of skin, 60, 66
UV light exposure and, 57, 63
small cell lung, c-myc
amplification in, 4, 11
small intestinalceliac disease and, 263, 267
Crohn’s disease and, 263, 267
familial adenomatous polyposis
and, 263, 267
hereditary nonpolyposis
colorectal cancer and, 263,
267
telomere dysfunction and
instability, 60, 66
therapy, active immunization for,
107, 112
urothelial
chromosome 9 deletions and,
283, 291
p53 mutations and, 283, 291
pRb alterations and, 283, 291
of vagina
DES in, 318, 325
HPV and, 315, 318, 323, 325
metastases in, 318, 325
radiation therapy for, 318, 326
stage II, 318, 326
staging for, 318, 325
of vulva
HPV infection in, 315, 323
lymph nodes, 319, 326
lymphovascular invasion and,
319, 326
prediction of, 319, 326
recurrence of, 319, 327
staging for, 319, 326
Cancer and Leukemia Group B
(CALGB), 447
Cancer-associated stromal
fibroblasts (CAF), 42, 54
characteristics of, 42, 54
Cancer cachexia, 565, 570, 571
pharmacological therapy of, 566,
571
Cancer immunotherapy, 107, 111
Cancer induction
high penetrance genes and, 60, 65
middle age and, 60, 65
young age and, 60, 65
Cancer of the Liver Italian
Program, 253, 257
Cancer pain management,
professional barriers to, 563,
568
Cancer patient
with paraplegia, measures for,
576, 579
rehabilitation of, 573–579
Cancer registry programs, 587
Cancer-related fatigue,
interventions for, 555, 559
Cancer-related thrombosis, 520,
523–524
Cancer stem cells (CSC), 23